期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 89, 期 3, 页码 355-365出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2010.314
关键词
-
资金
- NIDA NIH HHS [R01 DA022199, R01 DA022199-05, DA022199] Funding Source: Medline
- NIGMS NIH HHS [GM092655, U01 GM092655, U01 GM092655-01] Funding Source: Medline
The use of pharmacogenomic biomarkers can enhance treatment outcomes. Regulatory polymorphisms are promising biomarkers that have proven difficult to uncover. They come in two flavors: those that affect transcription (regulatory single-nucleotide polymorphisms (rSNPs)) and those that affect RNA functions such as splicing, turnover, and translation (termed structural RNA SNPs (srSNPs)). This review focuses on the role of srSNPs in drug metabolism, transport, and response. An understanding of the nature and diversity of srSNPs and rSNPs enables clinical scientists to evaluate genetic biomarkers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据